1104583-95-0

Basic information

• Product Name: 1-propenyl 2-acetylamino-6-O-benzyl-4-O-(2'-acetylamino-3'-O-benzyl-4',6'-O-benzylidene-2'-deoxy-β-D-glucopyranosyl)-3-O-[(R)-1-(carbonyloxy)ethyl]-2-deoxy-α-D-glucopyranoside
• Synonyms: 1-propenyl 2-acetylamino-6-O-benzyl-4-O-(2'-acetylamino-3'-O-benzyl-4',6'-O-benzylidene-2'-deoxy-β-D-glucopyranosyl)-3-O-[(R)-1-(carbonyloxy)ethyl]-2-deoxy-α-D-glucopyranoside
• CAS NO: 1104583-95-0
• Molecular Weight: 804.891
• Mol File: 1104583-95-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-propenyl 2-acetylamino-6-O-benzyl-4-O-(2'-acetylamino-3'-O-benzyl-4',6'-O-benzylidene-2'-deoxy-β-D-glucopyranosyl)-3-O-[(R)-1-(carbonyloxy)ethyl]-2-deoxy-α-D-glucopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: 1-propenyl 2-acetylamino-6-O-benzyl-4-O-(2'-acetylamino-3'-O-benzyl-4',6'-O-benzylidene-2'-deoxy-β-D-glucopyranosyl)-3-O-[(R)-1-(carbonyloxy)ethyl]-2-deoxy-α-D-glucopyranoside(1104583-95-0)
• EPA Substance Registry System: 1-propenyl 2-acetylamino-6-O-benzyl-4-O-(2'-acetylamino-3'-O-benzyl-4',6'-O-benzylidene-2'-deoxy-β-D-glucopyranosyl)-3-O-[(R)-1-(carbonyloxy)ethyl]-2-deoxy-α-D-glucopyranoside(1104583-95-0)

Safety Data

• Hazardous Substances Data: 1104583-95-0(Hazardous Substances Data)

Upstream product

• 1104583-93-8 1-propenyl 2-acetylamino-6-O-benzyl-4-O-(2'-acetylamino-3'-O-benzyl-4',6'-O-benzylidene-2'-deoxy-β-D-glucopyranosyl)-2-deoxy-3-O-[(R)-1-(ethoxycarbonyl)ethyl]-α-D-glucopyranoside 

Downstream Products

• 1104583-99-4 C₈₇H₁₀₀N₆O₂₂ 
• 1104583-97-2 C₉₀H₁₀₅N₇O₂₃ 

Relevant articles and documents

Synthesis of diaminopimelic acid containing peptidoglycan fragments and tracheal cytotoxin (TCT) and investigation of their biological functions

Bacterial cell wall peptidoglycan (PGN) is a potent immunostimulator and immune adjuvant. The PGN of Gram-negative bacteria and some Gram-positive bacteria contain meso-diaminopimelic acid (meso-DAP), and we have recently shown that the intracellular protein Nodi is a PGN receptor and recognizes DAPcontaining peptides. In this study, we achieved the synthesis of DAP-containing PGN fragments, including the first chemical synthesis of tracheal cytotoxin (TCT), GlcNAc-(β1-4)-(anhydro) Mur-NAc-L-Ala-γ-D-Glu-meso- DAP-D-Ala, and a repeating-unit of DAP-type PGN, GlcNAc-(β1-4)-MurNAc-L- Ala-γ-D-Glu-meso-DAP-D-Ala. For the synthesis of PGN fragments, we first established a new synthetic method for an orthogonally protected meso-DAP derivative, and then we constructed the glycopeptide structures. The ability of these fragments to stimulate human Nodi, as well as differences in Nodi recognition of the variety of synthesized ligand structures were examined. The results showed that the substitution of the N terminus of iE-DAP is necessary for stronger Nodi recognition, but the structure of the substituent seems not to be strictly recognized. The importance of the carboxyl group at the 2-position of DAP for human Nod1 stimulation was also shown.